6533b830fe1ef96bd1297af1

RESEARCH PRODUCT

Abatacept as Adjunctive Therapy in Refractory Polymyalgia Rheumatica.

Valérie DevauchelleMartin MichaudEric ToussirotDaniel Wendling

subject

musculoskeletal diseasesmedicine.medical_specialtyeducationImmunologyGiant Cell ArteritisPolymyalgia rheumaticaAbataceptDiagnosis DifferentialRheumatologyRefractoryimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectbusiness.industryAbataceptmedicine.diseaseCombined Modality TherapyPolymyalgia RheumaticaMethotrexatebusinesshormones hormone substitutes and hormone antagonistsmedicine.drug

description

Glucocorticoids (GCs) are the mainstay of treatment for patients with polymyalgia rheumatica (PMR).1 Despite their efficacy, GCs are associated with well-known adverse events and a substantial proportion of patients with PMR do not respond adequately, or are refractory, to initial GC treatment. GC-sparing agents in PMR are limited to methotrexate (MTX).1.

yearjournalcountryeditionlanguage
2021-09-17The Journal of rheumatology
10.3899/jrheum.210455https://pubmed.ncbi.nlm.nih.gov/34526393